Saturday, May 9, 2020

HOPS ((Humulus lupulus L. (Cannabaceae/Moraceae))


HERBAL 
MEDICINAL
PLANT







H O P S


Humulus lupulus L. (Cannabaceae/Moraceae)


























By

RETTODWIKART THENU







H O P S
(hahps)


Humulus lupulus L. (Cannabaceae/Moraceae)


SUMMARY AND PHARMACEUTICAL COMMENT
The chemistry of hops is well documented and is characterised by the bitter acid components of the oleo-resin. Documented pharmacological activities support the herbal uses, although evidence from robust clinical studies is limited. Excessive use of hops and use during pregnancy and lactation should be avoided in view of the limited toxicity data.

DESCRIPTION
Medicinal Parts: The medicinal parts are the glandular hairs separated from the infructescence, the whole dried female flowers, the fresh cones (preferably with few seeds) collected before the seeds ripen and the fresh or dried female inflorescence.
Flower and Fruit: The male flowers are yellowish-greenish, inconspicuous and about 5 mm in diameter. The female flowers are in richly blossomed, heavily branched inflorescence. The ovary, which has 2 long downy stigma, is surrounded at the base by a round compressed nutlet. A yellowish fruit cone grows from the female flower. The inside of the bracts is covered with small, glossy, light yellow glandular scales, which contain hop bitter (Lupulin).
Leaves, Stem and Root: The hop plant is a perennial. The annual shoots reach a height of 6 m (12 m when cultivated). The stems are pencil-thick, green and do not tum woody. They are covered in 6 rows of climbing barbs. The leaves are 3 to 5 Iobed, serrate and opposite.
Characteristics: Lupulin has a very strong odor and an extremely bitter taste.
Habitat: Indigenous to Europe, cultivated in Asia, U.S. and elsewhere.
Production: Hop cones consist of the whole dried female inflorescence of Humulus lupulus. After the harvest, the hops are dried on racks at temperatures of 30 to 60° C.

Origin: The hop plant is a perennial that is cultivated throughout the world.

SPECIES (FAMILY)
Humulus lupulus L. (Cannabaceae/Moraceae)

SYNONYM(S)
Humulus, Lupulus

PART(S) USED
Strobile

PHARMACOPOEIAL AND OTHER MONOGRAPHS
BHC 1992(G6)
BHP 1996(G9)
BP 2007(G84)
Complete German Commission E(G3)
ESCOP 2003(G76)
Martindale 35th edition(G85)
Ph Eur 2007(G81)
LEGAL CATEGORY (LICENSED PRODUCTS)
GSL(G37)


CONSTITUENTS/COMPOUND

CONSTITUENTS
The following is compiled from several sources, including General References G2, G6 and G52.
·         Flavonoids Astragalin, kaempferol, quercetin, quercitrin and rutin.
·         Chalcones Isoxanthohumol, xanthohumol, 6-isopentenylnaringenin, 30-(isoprenyl)-20, 4-dihydroxy-40, 60-dimethoxychalcone, 20,60-dimethoxy-4, 40-dihydroxychalcone.(1)
·         Oleo-resin 15-30%. Bitter principles (acylphloroglucides) in a soft and hard resin. The lipophilic soft resin consists mainly of aacids (e.g. humulone, cohumulone, adhumulone, prehumulone, posthumulone), b-acids (e.g. lupulone, colupulone, adlupulone), and their oxidative degradation products including 2-methyl-3- buten-2-ol(2, 3, G52) The hard resin contains a hydrophilic d-resin and _-resin.
·         Tannins 2–4%. Condensed; gallocatechin identified.(4)
·         Volatile oils 0.3–1.0%. More than 100 terpenoid components identified; primarily (at least 90%) b-caryophyllene, farnescene and humulene (sesquiterpenes), and myrcene (monoterpene).
·         Other constituents Amino acids, phenolic acids, gamma-linoleic acids, lipids and oestrogenic substances (disputed).(5) It has been stated that only low amounts of 2-methyl-3-buten-2- ol, the sedative principle identified in hops, are present in sedative tablets containing hops.(2) However, it is thought that 2-methyl-3- buten-2-ol is formed in vivo by metabolism of the a-bitter acids and, therefore, the low amount of 2-methyl-3-buten-2-ol in a preparation may not indicate low sedative activity.(6) Interestingly, relatively high concentrations of 2-methyl-3-buten-2-ol were found in bath preparations, suggesting that high concentrations of 2- methyl-3-buten-2-ol may be achieved in both tea and bath products containing hops.(2)

COMPOUNDS
·         Acylphloroglucinols (10%)
·         Alpha-bitter acids: including, among others, humulone, cohumulone, adhumulone
·         Beta-bitter acids: including, among others, lupulone, colupulone, adlupulone
·         Volatile oil (0.3-1.0%): very complex in makeup, chief components myrcene, humulene, beta-caryophyllene, undecane-2-on, furthermore 2-methyl-but-3-en-ol (particularly following storage, as breakdown product of the acylphloroglucinols)
·         Resins (oxidation products of the bitter acids)
·         Phenolic acid: including, among others, ferulic acid, caffeic acid and their derivatives, for example, chlorogenic acid
·         Tannins: oligomeric proanthocyanidines
·         Flavonoids: including, among others, xanthohumole

ACTIVITIES (HOPS) —
Allergenic (f; CRC); Analgesic (1; BGB; CRC; MAD; PNC; WAM); Anaphrodisiac (1; APA; CRC; MAD); Antibacterial (1; APA; CAN; WAM); Antiseptic (1; CRC; FAD); Antispasmodic (1; APA; BGB; WAM); Antitumor (1; APA); Aperitif (1; PH2; SKY); Bitter (1; CRC; PNC); Diaphoretic (f; CRC); Digestive (1; APA; WAM); Diuretic (f; CRC; PNC); Emmenagogue (f; MAD); Emollient (f; APA); Estrogenic (1; APA; FNF; PH2; WAM); Expectorant (f; PED); Fungicide (1; APA; PH2); Hypnotic (1; CAN; CRC); Lactagogue (1; WAM); Laxative (f; MAD); Litholytic (f; MAD); Myorelaxant (1; APA; CAN); Narcotic (1; CAN; CRC); Nervine (f; CRC); Secretagogue (f; PH2); Sedative (2; APA; KOM; WAM); Soporific (1; BGB; CRC); Stomachic (f; CRC; PH2); Tonic (f; CRC; MAD); Tranquilizer (1; KOM; SHT); Uterotonic (f; MAD); Vermifuge (f; CRC).


ACTIONS
Hops have been used by the food and liquor industries as a fl avoring for food and beer. Medicinal uses for hops are described here, although little reliable research exists for any uses or actions.
Estrogenic Action
Hops are believed to possess estrogen-like activity due to the phytoestrogen components of the hop plant and its ability to exert direct estrogenic effects (Zava et al, 1998). One older study demonstrated estrogenic activity in an acid fraction of the plant (Zenisek et al, 1960). However, many of the other available studies contain confl icting information regarding the estrogenic action. At this point it is uncertain whether the hop plant does exert estrogen-like activity.
Sedative/Hypnotic Action
The sedative/hypnotic effects of hops may be due to the volatile oils present in the plant. The same volatile oils may also be responsible for the antispasticity effect. Hops possess a pentobarbital sleep-enhancing effect without infl uencing motor behavior and an antideppresant action, when studied in the laboratory (Zanoli et al, 2005).
Antimicrobial Action
One small study shows that the antimicrobial effects of hops result from the bitter acid components (volatile oils) lupulone, humulene, and linalool (Leung, 1980).
Other Actions
Hops did not improve bone parameters in laboratory animals (Figard et al, 2007).

INDICATIONS  

INDICATIONS (HOPS) —
Adenopathy (f; JLH); Anemia (f; MAD); Angina (f; MAD); Anorexia (1; APA; BGB; SKY); Anxiety (2; APA; BGB; WAF; SHT); Arthrosis (f; MAD); Asbestosis (2; BGB); Asthma (f; MAD); Atony (f; MAD); Bacteria (1; APA; CAN; CRC; WAM); Boil (f; CRC; FAD); Bruise (f; CRC; FAD; MAD); Calculus (f; CRC); Cancer (1; APA; JLH); Cancer, breast (f; JLH); Cancer, face (f; JLH); Cancer, liver (f; JLH); Cancer, lymph (f; JLH); Cancer, spleen (f; JLH); Cancer, stomach (f; JLH); Cancer, uterus (f; CRC); Cardiopathy (f; MAD); Catarrh (f; MAD); Chlorosis (f; MAD); Climacteric (1; HHB); Colitis (f; CAN); Constipation (f; MAD); Cough (f; CRC; FAD); Cramp (1; APA; BGB; FAD; WAM); Crural Ulcer (f; CAN); Cystosis (f; APA; CRC; MAD); Debility (f; CRC); Delirium (f; CRC); Depression (f; CAN); Dermatosis (f; PH2); Diabetes (f; MAD); Diarrhea (1; APA; CRC); Dysentery (2; BGB; CRC); Dysmenorrhea (f; APA); Dyspepsia (1; APA; BGB; WAM); Earache (f; CRC); Edema (f; MAD); Enterosis (f; MAD; PH2); Enuresis (f; MAD); Fever (f; CRC; FAD); Fit (f; CRC); Fungus (1; APA; PH2); Gas (f; MAD); Gastrosis (f; JLH); Gonorrhea (f; MAD); Gravel (f; BGB); Headache (1; BGB; PH2; WAM); Hepatosis (f; JLH; MAD); Hyperactivity (1; WAM); Hypochondria (f; MAD); Hysteria (f; CRC; MAD); Impotence (f; MAD); Induration (f; JLH); Infection (1; APA; CRC; PH2); Inflammation (f; CRC; FAD; PH2); Insomnia (2; APA; CRC; KOM; SHT; WAM); Jaundice (f; CRC; MAD); Leprosy (2; APA; BGB; CRC); Mastosis (f; BGB; JLH); Menopause (f; HHB); Morning Sickness (f; MAD); Mucososis (f; PH2); Mycosis (1; APA; PH2); Nephrosis (f; BGB); Nerve (f; CRC); Nervousness  (2; APA; KOM; PHR; PH2; SHT; WAM); Neuralgia (1; CAN; CRC); Neurasthenia (f; MAD); Neurosis (f; APA); Nymphomania (f; MAD); Oligolactea (1; WAM); Onanism (f; MAD); Pain (1; BGB; CRC; MAD; PNC; WAM); Priapism (f; CAN; PH2); Prostatosis (f; MAD); Pulmonosis (f; CRC); Restlessness (2; KOM; SHT; WAM) (with tension headache and/or dyspepsia) (1; CAN); Rheumatism (f; BGB; CRC; FAD; MAD); Satyriasis (f; MAD); Scirrhus (f; JLH); Scrofula (f; MAD); Silicosis (2; BGB); Sore (f; JLH; PH2); Splenosis (f; JLH; MAD); Spermatorrhea (f; MAD); Stomachache (f; MAD); Stone (f; MAD); Stress (1; APA); Swelling (f; JLH); Toothache (f; CRC); Tuberculosis (1; APA; BGB; CRC); Tumor (1; APA; CRC); Ulcer (f; CRC); Ulcus cruris (f; PH2); Uterosis (f; BGB); VD (f; MAD); Water Retention (f; CRC; MAD; PNC); Worm (f; CRC).

INDICATIONS AND USAGE
Approved by Commission E:
• Nervousness and insomnia
Unproven Uses: Used as a bitter and stomachic to stimulate the appetite and increase the secretion of gastric juices. In folk medicine, Hops has been used internally for nerve pain, priapism, inflammation of the intestinal mucous membrane and tension headaches and used externally for ulcus cruris, ulcers and skin abrasions.
Homeopathic Uses: Humulus lupulus is found in preparations for treating nervousness and insomnia.

PRECAUTIONS AND ADVERSE REACTIONS
No health hazards or side effects are known in conjunction with the proper administration of designated therapeutic dosages. The fresh plant has a sensitizing effect (hoppicker's disease), which may occur, more rarely, with the dust of the drug as well.


USES

USES
Hops traditionally have been used as an analgesic, an anthelmintic, a sedative/ hypnotic to treat insomnia, and for attention defi cit–hyperactivity disorder. It is also used to treat menopausal symptoms and to wean patients off conventional sedative prescriptions.
FOOD USE
Hops are listed by the Council of Europe as a natural source of food flavouring (category N2). This category indicates that hops can be added to foodstuffs in small quantities, with a possible limitation of an active principle (as yet unspecified) in the final product.(G16) Previously, hops has been listed as GRAS (Generally Recognised As Safe).(G65)
HERBAL USE
Hops are stated to possess sedative, hypnotic and topical bactericidal properties. Traditionally, they have been used for neuralgia, insomnia, excitability, priapism, mucous colitis, topically for crural ulcers, and specifically for restlessness associated with nervous tension headache and/or indigestion. The German Commission E approved use for mood disturbances such as restlessness and anxiety as well as sleep disturbances.(G3) Hops are used in combination with valerian root for nervous sleeping disorders and conditions of unrest.(G3)

PRODUCT AVAILABILITY
Cut herb, dry extract, extract, powdered dry herb, tea
Plant Part Used: Whole hops


DOSAGE

DOSAGES
       Adult PO infusion: pour 8 oz boiling water over 0.4 g (1 tsp) ground hops cone, let stand 15 min
       Adult PO extract: 2-4 mg
       Adult PO cut herb: 0.5 g as a single dose (Blumenthal, 1998)
       Adult PO topical: apply to affected area as needed

DOSAGE
Dosages for oral administration (adults) for traditional uses recommended in contemporary standard herbal reference texts are given below.
       Dried strobile 0.5 g as an infusion two to four times daily.(G76)
       Liquid extract 0.5–2.0 mL (1 : 1 in 45% alcohol) up to three times daily.(G76)
       Tincture 1–2mL (1 : 5 in 60% alcohol) up to three times daily.(G76)




DOSAGE
Mode of Administration: Comminuted drug, powdered drug or dry extract powder for infusions or decoctions or other preparations; liquid and solid preparations for internal use and externally for bath additives. Hops is often found in combination with other sedatives.
How Supplied:
       Liquid extract — drug: 1:1 45% ethanol (V/V) (BHP83).
       Tincture — drug 1:5 60% ethanol (V/V) (BHP83)
Preparation: To prepare an infusion, boiling water is poured over the ground hop cones and left to draw for 10 to 15 minutes (1 teaspoonful is equal to 0.4 gm drug).
Daily Dosage: For most indications, a single dose of 0.5 gm is given.
To promote sleep, a single dose of 1 to 2 gm drug is given; liquid extract: single dose: 0.5 to 2 ml; tincture: single dose: 1 to 2 ml.
Tea: 1 cup before bedtime for 2 to 3 days.
^ Homeopathic Dosage: 5 drops, 1 tablet or 10 globules every 30 to 60 minutes (acute) or 1 to 3 times daily (chronic); parenterally: 1 to 2 ml sc acute, 3 times daily; chronic: once a day (HAB1).
Storage: Protect from light and moisture in well-sealed containers.

DOSAGES (HOPS) —
500 mg/day (SF); 2–6 tsp fresh flower (PED); 1–3 g dry flower (PED); 2 g dry flower:10 ml alcohol/10 ml water (PED); 1–2 tsp inflorescence/cup water (SKY; WIC); 0.5–1 (–2 as hypnotic) g hops, or in tea (CAN; SKY); 0.5–1 g powdered herb;
0.5–15 g cones (PNC); 1 tsp (0.4 g) cone cup (PH2); 0.5–2.0 ml liquid hops extract (1:1 in 45% ethanol) (CAN); 0.5–4 ml liquid inflorescence extract (PNC);
1–2 ml hops tincture (1:5 in 60% ethanol) 1–3 ×/day (CAN; SKY); 2–4 ml inflorescence tincture (PNC); 2–4 g inflorescence tincture (MAD); 120–300 mg lupulin (PNC). Cones = flowers = dry infloresences.

DOSAGE RANGE
• Infusion or decoction: 0.5 g in 150 mL water.
• Fluid extract (1:1) (g/mL): 0.5 mL/day; 0.5–1 mL three times daily.
• Tincture (1:5) (g/mL): 1–2.5 mL/day.
• Also used as a bath additive (4 g hops in a concentrated extract) and in pillows.


PHARMACOLOGICAL ACTIONS

IN VITRO AND ANIMAL STUDIES
Antibacterial activity, mainly against Gram-positive bacteria, has been documented for hops, and attributed to the humulone and lupulone constituents.(7) The activity of the bitter acids against Gram-positive bacteria is thought to involve primary membrane leakage. Resistance of Gram-negative bacteria to the resin acids is attributed to the presence of a phospholipid-containing outer membrane, as lupulone and humulone are inactivated by serum phospholipids.(7) Structure–activity studies have indicated the requirement of a hydrophobic molecule and a six-membered central ring for such activity.(8)
Figure 1. Hops (Humulus lupulus).
The humulones and lupulones are thought to possess little activity towards fungi or yeasts. However, antifungal activity has been documented for the bitter acids towards Trichophyton, Candida, Fusarium and Mucor species.(9) Flavonone constituents have also been documented to possess antifungal activity towards Trichophyton and Mucor species, and antibacterial activity towards Staphylococcus aureus.(10) Antispasmodic activity has been documented for an alcoholic hops extract on various isolated smooth muscle preparations.(11) Hops have been reported to exhibit hypnotic and sedative properties.(G41) 2-Methyl-3-buten-2-ol, a bitter acid degradation product, has been identified as a sedative principle in hops.(2, 3) 2-Methyl-3-buten-2-ol has been shown to possess narcotic properties in mice and motility depressant activity in rats, with the latter not attributable to a muscle-relaxant effect.(12) It has also been suggested that isovaleric acid residues present in hops may contribute towards the sedative action. In mice, hops extract administered intraperitoneally (100, 250, 500 mg/kg) 30 minutes prior to a series of behavioural tests, resulted in a dose-dependent suppression of spontaneous locomotor at doses of 250 mg/kg for up to one hour.(13) The time for mice to be able to remain on a rota rod was decreased by 59% and 65% at doses of 250 mg/kg and 500 mg/kg, respectively. The time of onset of convulsions and survival time after administration of pentylenetetrazole (100 mg/kg) was significantly lengthened. Hops extract (35 mg/kg, intraperitoneal administration) produced a dose-dependent increase in sleeping time in mice treated with pentobarbitol. An antinociceptive effect was noted by increased latency of licking forepaws in hotplate tests and hypothermic activity observed from a time-dependent fall of rectal temperature at a dose of 500 mg/kg.(13)
Hops have previously been reported to possess oestrogenic constituents.(5) However, when a number of purified components, including the volatile oil and the bitter acids, were examined using the uterine weight assay in immature female mice, no oestrogenic activity was found.(5)

CLINICAL STUDIES
Clinical research assessing the effects of hops is limited and rigorous randomised controlled clinical trials are required. Clinical studies have generally assessed hops given in combination with one or more additional herbs. For example, hops has been reported to improve sleep disturbances when given in combination with valerian (see Valerian, Clinical studies).(14)

Figure 2.  Hops – dried drug substance (strobile).
Hops, in combination with chicory and peppermint, has been documented to relieve pain in patients with chronic cholecystitis (calculous and non-calculous).(15) A herbal product containing a mixture of plant extracts, including hops and uva-ursi, and alphatocopherol acetate was reported to improve irritable bladder and urinary incontinence.(16) However, these observations require confirmation in robust clinical studies.

EXTRACTS (HOPS) —
 The LD50 for orally administered hop extract or lupulones in mice is ~500–3500 mg/kg (roughly 1/2 to 20th as toxic as caffeine). Ethanol extract antispasmodic and myorelaxant. Antibacterial activity has been documented for hops, humulone, and lupulone against Gram positive bacteria. The bitter acids exhibit antifungal activity against Candida, Fusarium, Mucor, and Trichophyton. The flavanones are antistaphylococcic and antifungal (Mucor and Trichophyton). Hops sedative and hypnotic, and motility-depressant properties are attributed to 2-methyl-3-buten-2-ol. Isovaleric acid may contribute to the sedativity. Hops reportedly contain several sedative, analgesic, anesthetic, and anodyne compounds as well. Piperidine, quercitrin, and ursolic acid may depress the CNS. Hops improve human sleep performance in combination with valerian and the hops are apparently effective in baths (I’d suggest in combination with dilute lavender and lemonbalm). With uva ursi and alpha-tocopherol acetate, hops gave excellent results for 772 of 915 patients with irritable bladder and urinary incontinence. Combined with the Biblical chicory and peppermint, hops documentably relieves pain in chronic cholecystosis (calculous and noncalculous).

CONTRAINDICATIONS, INTERACTIONS, AND SIDE EFFECTS 

CONTRAINDICATIONS, INTERACTIONS, AND SIDE EFFECTS
Class 2d (AHP). “Hazards and/or side effects not known for proper therapeutic dosages” (PH2). None reported (KOM; PHR; PIP). Some caution against use in depression (AHP). Mild allergies or dermatosis may result from contact. Oleo-resin reported to be allergenic, possibly causes dermatosis (CAN). Respiratory allergy caused by handling of hop cones (fresh hops oil, humulone, lupulone, and myrcene produce positive skin patch tests). Pollen can cause contact dermatosis. They suggest that hops be contraindicated in depressive states as the sedative effect of hops may aggravate or accentuate symptoms. “The sedative effect may potentiate the effects of existing sedative therapy and alcohol” (CAN). In vitro antispasmodic activity on the uterus has been documented. Because of uterine activity, its use in pregnancy and lactation is to be avoided. “Excessive use should be avoided in view of the limited toxicity data” (CAN). Avoid if pregnant (WAM). Do not use if suffering estrogen-dependent disorders (WAM).

CONTRAINDICATIONS
Pregnancy category is 3; breastfeeding category is 3A.
Hops should not be used by persons who are hypersensitive to this product; persons who have breast, uterine, or cervical cancers; or those who suffer from a depressive condition. Hops are for short-term or intermittent use only. Use caution to avoid sedation in infants.

SIDE EFFECTS/ADVERSE REACTIONS
CNS: Sedation, dizziness, decreased reaction time
GI: Nausea, vomiting, anorexia
INTEG: Hypersensitivity reactions, including dermatitis and anaphylaxis

INTERACTIONS
Drug
Antidepressants, antipsychotics, antihistamines, alcohol, CNS depressants: Hops may cause increased central nervous system effects when taken concurrently with antidepressants, antipsychotics, antihistamines, alcohol, CNS depressants.
Cytochrome P450 (carbamazepine, bupropion, orphenadrine, cyclophosphamide, citalopram, azole antifungals, macrolide antibiotics, omeprazole, warfarin, theophylline): Hops may decrease the levels of these drugs.
Estrogens: Hops may cause increased hormonal levels when taken in conjunction with estrogen (theoretical).
Iron salts: Hops tea may decrease the absorption of iron salts; separate by at least 2 hours.
Herb
Sedative herbs: Hops may increase sedation when used with other sedating herbs (theoretical) (Jellin et al, 2008).

SIDE-EFFECTS, TOXICITY
There is a lack of clinical safety and toxicity data for hops and further investigation of these aspects is required. Respiratory allergy caused by the handling of hop cones has been documented;(17) a subsequent patch test using dried, crushed flowerheads proved negative. Positive patch test reactions have been documented for fresh hop oil, humulone, and lupulone. Myrcene, present in the fresh oil but readily oxidised, was concluded to be the sensitising agent in the hop oil.(G51) Contact dermatitis to hops has long been recognised(G51) and is attributed to the pollen.(G41) Small doses of hops are stated to be non-toxic.(G42) Large doses administered to animals by injection have resulted in a soporific effect followed by death, with chronic administration resulting in weight loss before death.(G39)

EFFECTS
The drug is a sedative and therefore has sleep-inducing effect. This effect, however, strongly depends on the quality of the extract used. In animal experiments, the 2-methyl-3-buten-2-ol exhaled by the plant caused a long and deep narcotic sleep after a short period of excitation. The hop bitter acids are antibacterial and antimycotic. They stimulate the secretion of gastric juices. In animal experiments, a strong spasmolytic effect on the smooth muscle of the intestinal tract has been reported. An estrogenic principle is considered plausible.

CONTRA-INDICATIONS, WARNINGS
Allergic reactions have been reported for hops, although only following external contact with the herb and oil. Drug interactions None documented. However, the potential for preparations of hops to interact with other medicines administered concurrently, particularly those with similar or opposing
effects, should be considered. There are some conflicting data on the oestrogenic activity of hops,(5) although 8-prenylnaringenin, documented as a constituent of hops, has been shown to have oestrogenic activity in preclinical studies.(G76) Concern has been expressed that herbs with oestrogenic effects may stimulate breast cancer growth and oppose action of competitive oestrogen
receptor antagonists such as tamoxifen.(18) However, this requires confirmation.
Pregnancy and lactation In vitro antispasmodic activity on the uterus has been documented. In view of this and the lack of toxicity data, the use of hops during pregnancy and lactation should be avoided.


CLIENT CONSIDERATIONS

ASSESS
·      Assess the reason the client is using hops.
·      Assess for hypersensitivity reactions and dermatitis. If present, discontinue the use of hops and administer an antihistamine or other appropriate therapy.
·      Assess for anaphylaxis.
·      Assess for central nervous system reactions: sedation, dizziness, and decreased reaction time.
·      Assess for medications used (see Interactions).

ADMINISTER
·      Instruct the client to store hops in a cool, dry place, away from heat and moisture.

TEACH CLIENT/FAMILY
·      Inform the client that pregnancy category is 3 and breastfeeding category is 3A.
·      Caution the client to avoid sedation in the infant.
·      Advise the client not to perform hazardous tasks such as driving or operating heavy machinery if sedation, dizziness, or decreased reaction time occurs.


PREPARATIONS

PROPRIETARY SINGLE-INGREDIENT PREPARATIONS
Russia: Novo-Passit (Ново-Пассит). Switzerland: Klosterfrau Nervenruh Dragees.

PROPRIETARY MULTI-INGREDIENT PREPARATIONS
Australia: Extralife Sleep-Care; Humulus Compound; Natural Deep Sleep; Pacifenity; Passiflora Complex; Passionflower Plus; Prosed-X; Relaxaplex. Austria: Baldracin; Baldrian AMA; Hova; Montana; Nervenruh; Nerventee St Severin; Sedadom; Wechseltee St Severin. Canada: Herbal Sleep Aid; Herbal Sleep Well. Chile: Valupass. Czech Republic: Baldracin; Detsky Caj s Hermankem; Fytokliman Planta; Novo-Passit; Sanason; Schlaf- Nerventee N; Species Nervinae Planta; Valofyt Neo; Visinal. France: Nostress. Germany: Ardeysedon; Avedorm duo; Baldrian-Dispert Nacht; Baldriparan N Stark; Biosedon; Boxocalm; Cefasedativ; Dormeasan; Dormoverlan; Gutnacht; Ilja Rogoff; Klosterfrau Beruhigungs Forte; Kytta-Sedativum; Leukona-Beruhigungsbad; Luvased; Moradorm S; Nervendragees; Nervenkapseln; Nervinfant N; Nervoregin forte; Pascosedon; Schlaf- und Nerventee; Sedacur; Sedaselect D; Selon; Sensinerv forte; Valdispert comp; Valeriana mild; Valverde Baldrian Hopfen bei Einschlafstorungen und zur Beruhigung; Vivinox Day. Hungary: Hova. Israel: Nerven-Dragees. Italy: Emmenoiasi. Mexico: Nervinetas. Russia: Doppelherz Vitalotonik (Доппельгерц Виталотоник); Sanason (Санасон). South Africa: Avena Sativa Comp. Switzerland: Baldriparan; Dormeasan; Dragees pour le coeur et les nerfs; Dragees pour le sommeil; Dragees sedatives Dr Welti; Hova; Hyperiforce comp; Nervinetten; ReDormin; Relaxo; Soporin; Tisane calmante pour les enfants; Tisane pour le sommeil et les nerfs; Valverde Coeur; Valverde Sommeil; Zeller Sommeil. UK: Anased; Avena Sativa Comp; Boots Alternatives Sleep Well; Boots Sleepeaze Herbal Tablets; Calmanite Tablets; Fenneherb Newrelax; Gerard House Serenity; Gerard House Somnus; HRI Calm Life; HRI Night; Kalms Sleep; Kalms; Napiers Sleep Tablets; Napiers Tension Tablets; Natrasleep; Newrelax; Nodoff; Nytol Herbal; Quiet Days; Quiet Life; Quiet Nite; Quiet Tyme; Relax Bþ; Sleepezy; Slumber; Sominex Herbal; Stressless; Unwind Herbal Nytol; Valerina Night-Time; Ymea. Venezuela: Lupassin; Nervinetas.




REFERENCE 

Barnes, J., Anderson, L. A., and Phillipson, J. D. 2007. Herbal Medicines Third Edition. Pharmaceutical Press. Auckland and London.

Duke, J. A. with Mary Jo Bogenschutz-Godwin, Judi duCellier, Peggy-Ann K. Duke. 2002. Handbook of Medicinal Herbs 2nd Ed. CRC Press LLC. USA.

Gruenwald, J., Brendler, T., Jaenicke, Ch. 2000.  PDR for Herbal Medicines.  Medical Economics Company, Inc. at Montvale, NJ 07645-1742. USA

Linda S-Roth. 2010. Mosby’s Handbook Of Herbs & Natural Supplements, Fourth Edition. Mosby Elsevier. USA.




No comments:

Post a Comment